arrow
K

Katharina Boch

Department of Dermatology
H指数:12
被引数:718

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Differential risk signals of cutaneous adverse drug reactions among β-lactam antibiotics: ceftriaxone shows increased signals for SJS/TEN in clinical and real-world cohorts

β-内酰胺类抗生素间皮肤不良反应的差异性风险信号:头孢曲松在临床和真实世界队列中显示出SJS/TEN风险信号增加

2026-09-030
OA
Klinisches und immunpathologisches Spektrum des Immunglobulin-M-Pemphigoids: eine multizentrische Fallserie

IgM型天疱疮的临床和免疫病理谱:一项多中心病例系列

2025-12-110
OAAI
Clinical and immunopathological spectrum of immunoglobulin M pemphigoid: a multicenter case series

免疫球蛋白M类天疱疮的临床和免疫病理学谱:一项多中心病例系列研究

2025-08-060
OA
S3 guideline: Diagnosis and treatment of epidermal necrolysis(Stevens-Johnson syndrome and toxic epidermal necrolysis) -Part 2: Supportive therapy of EN in the acute and post-acute stages

S3指南: 表皮坏死松解症 (stevens-johnson综合征和中毒性表皮坏死松解症) 的诊断和治疗.第2部分: 急性和急性后阶段EN的支持治疗

2024-11-070
OAAI
S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 2: Supportive therapy of EN in the acute and post-acute stages
2024-10-170
OAAI
S3-Leitlinie: Diagnostik und Therapie der epidermalen Nekrolyse (Stevens-Johnson-Syndrom und toxisch epidermale Nekrolyse) - Teil 1: Diagnostik, initiales Management und immunmodulierende Systemtherapie

S3指南:表皮坏死(Stevens-Johnson综合征和中毒性表皮坏死)的诊断与治疗——第1部分:诊断、初始管理和免疫调节系统性治疗

2024-10-110
OAAI
S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 1: Diagnosis, initial management, and immunomodulating systemic therapy
2024-09-230
OAAI
High throughput screening identifies repurposable drugs for modulation of innate and acquired immune responses
2024-09-010
OA
Serum reactivity in dermatitis herpetiformis: an international multicentre study
2023-10-042
PRE
Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases(vol 13, 1099535, 2022)
2022-11-303
OAAI